Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076171 | 1.00 | UGT2B7 (0.55) | UGT2B7AKR1B1AKR1C3AKR1C2MMP9 | |
| SCHEMBL11538804 | 0.86 | PTGS2 (0.70) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL17583583 | 0.85 | UGT2B7 (0.53) | UGT2B7AKR1B1AKR1C3AKR1C2MMP9 | |
| SCHEMBL10025981 | 0.84 | AKR1B1 (0.69) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL4679446 | 0.84 | AKR1B1 (0.69) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL1217681 | 0.84 | AKR1B1 (0.69) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL12431128 | 0.84 | AKR1B1 (0.69) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL30717241 | 0.84 | AKR1B1 (0.69) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL17585039 | 0.82 | TDP1 (0.62) | UGT2B7MMP9 | |
| Hydrochloric Acid SCHEMBL27401798 | 0.82 | AKR1B1 (0.67) | UGT2B7AKR1B1AKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | claimed |
| CN-101184711-A | Nucleophilic heterocyclic carbene derivatives of pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-05-21 | — | — | CN | claimed |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2006-12-21 | — | — | US | claimed |
| CN-115385765-B | Synthesis method of alkylaryl ketone | 南京工业大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-115385765-A | Synthesis method of alkyl aryl ketone | 南京工业大学 | 2022-11-25 | — | — | CN | disclosed |
| US-9802894-B2 | α-glucosidase inhibitors | KING SAUD UNIVERSITY (SA) | 2017-10-31 | — | — | US | disclosed |
| US-20170088516-A1 | ALPHA-GLUCOSIDASE INHIBITORS | KING SAUD UNIVERSITY (SA) | 2017-03-30 | — | — | US | disclosed |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-03-17 | — | — | US | disclosed |
| WO-2016016414-A1 | METHOD FOR CREATING UNCATALYZED CARBON-CARBON BONDS FROM CARBONYLATED COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2016-02-04 | — | — | WO | disclosed |
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NISCH, DDT, TEC | UGT2B7 1159/4885AKR1B1 2477/4885AKR1C3 1151/4885 |
| US-20170088516-A1 | ALPHA-GLUCOSIDASE INHIBITORS | GBA3, GANAB, GANC | UGT2B7 94/4885AKR1B1 354/4885AKR1C3 1005/4885 |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | NDC1, DDC, PDCD1LG2 | UGT2B7 2800/4885AKR1B1 2093/4885AKR1C3 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.